Get the Stockscreener App
23.35
2.10%
0.48
After Hours:
23.18
-0.17
-0.73%
Evommune Inc stock is traded at $23.35, with a volume of 391.90K.
It is up +2.10% in the last 24 hours and down -8.00% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$22.87
Open:
$22.87
24h Volume:
391.90K
Relative Volume:
1.14
Market Cap:
$841.03M
Revenue:
$13.00M
Net Income/Loss:
$-68.87M
P/E Ratio:
-10.48
EPS:
-2.2276
Net Cash Flow:
$-76.68M
1W Performance:
+10.56%
1M Performance:
-8.00%
6M Performance:
+20.30%
1Y Performance:
+0.00%
1-Day Range:
$22.43
$23.55
1-Week Range:
$21.26
$24.01
52-Week Range:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.35 | 823.74M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
H.C. Wainwright reiterates Evommune stock rating on trial progress By Investing.com - Investing.com Nigeria
Number of shareholders of Evommune, Inc. – BX:EVMN - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
EVMN Technical Analysis | Trend, Signals & Chart Patterns | EVOMMUNE INC (NYSE:EVMN) - ChartMill
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Raises Target Price to $50 - Moomoo
Here's Why We're Not Too Worried About Evommune's (NYSE:EVMN) Cash Burn Situation - Moomoo
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
TradingKey - TradingKey
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth - Yahoo Finance
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Evommune (NYSE:EVMN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Evommune (EVMN) Earnings Date and Reports 2026 - MarketBeat
Evommune (EVMN) Earnings Decline Versus 85.7% Revenue Growth Tests Bullish Narratives - Sahm
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune stock rises 3% on beating first quarter loss estimates By Investing.com - Investing.com Canada
Evommune stock rises 3% on beating first quarter loss estimates - Investing.com
Evommune : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline - TipRanks
Earnings Flash (EVMN) Evommune, Inc. Reports Q1 Revenue $0K - marketscreener.com
Evommune’s First Quarter 2026 Financial Results and Business Activities Released on StockTitan.net - geneonline.com
Evommune (NYSE: EVMN) updates S-1 with Q1 results and $117M raise - Stock Titan
Evommune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Evommune (NYSE: EVMN) raises $117M and funds operations into 2028 - Stock Titan
Evommune (NYSE: EVMN) details Q1 2026 loss, cash runway and Phase 2b catalysts - Stock Titan
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights - Yahoo Finance
20,702,560 Common Stock of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Certain Options of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Stifel initiated coverage on Evommune with a new price target - Quantisnow
Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo
Evommune and BillionToOne climb on trading debut - MSN
Evommune surges on mid-stage trial win for eczema therapy - MSN
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat
[EFFECT] Evommune, Inc. SEC Filing - Stock Titan
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks
Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan
EVMN Options Chain — NYSE:EVMN - TradingView
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm
EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):